Cite
HARVARD Citation
Tobin, J. et al. (2022). Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). Journal of medical economics. pp. 1030-1038. [Online].